EntryPoint Capital LLC Invests $330,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

EntryPoint Capital LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 463 shares of the biopharmaceutical company's stock, valued at approximately $330,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Intact Investment Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $356,000. Principal Financial Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the period. Golden State Equity Partners grew its holdings in Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after purchasing an additional 1,272 shares in the last quarter. Fagan Associates Inc. grew its holdings in Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after purchasing an additional 3,832 shares in the last quarter. Finally, ABC Arbitrage SA purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $1,510,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $17.23 during trading on Tuesday, reaching $617.00. 1,059,572 shares of the company were exchanged, compared to its average volume of 677,760. Regeneron Pharmaceuticals, Inc. has a 52 week low of $615.00 and a 52 week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $681.52 and a 200 day moving average of $788.06. The stock has a market cap of $67.45 billion, a P/E ratio of 16.12, a PEG ratio of 2.34 and a beta of 0.27.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.86 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.57%. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.

Analyst Ratings Changes

A number of research firms have weighed in on REGN. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. TD Cowen reduced their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Finally, BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.